Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
Rankning i aktier #7143
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Aktiekurs
$40.39
Senast synkroniserad: 2023-08-18
Marknadsvärde
$1.70B
Förändring (1 dag)
0.00%
Förändring (1 år)
0.00%
Land
US
Handel Chinook Therapeutics, Inc. (KDNY)

Kategori

EPS för Chinook Therapeutics, Inc. (KDNY)
EPS per 2026 TTM: 0
Enligt Chinook Therapeutics, Inc.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) 0. Vid slutet av 2026 hade bolaget ett EPS på 0, lika med EPS från 2026 som var 0.
EPS-historik för Chinook Therapeutics, Inc. från 2026 till 2026
EPS vid slutet av varje år
År EPS Ändra
Inte tillräckligt med data för de angivna datumen.
EPS för liknande företag eller konkurrenter
Företag EPS EPS-differens Land
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH